PhaseBio Pharmaceuticals, Inc. announced the appointment of Alex C. Sapir to its board of directors. Additionally, Bibhash Mukhopadhyay, Ph.D., has stepped down from his role as a director. Mr. Sapir has more than 25 years of experience building commercial stage pharmaceutical organizations. He is currently the chief executive officer of ReViral Therapeutics, an antiviral company focused on discovering and developing therapeutics to treat respiratory syncytial virus (RSV). He was previously the president and chief executive officer at Dova Pharmaceuticals, a pharmaceutical company focused on developing and commercializing drug candidates for diseases where there is a high unmet medical need. In addition to joining the PhaseBio board, Mr. Sapir was also appointed as a member of its audit committee.